Monitor for future commercial uptake metrics (e.g., number of patients treated, batch production rates) to assess ZEVASKYN's real-world adoption. The addition of a top-tier medical center may support long-term penetration, but current insider selling and lack of sales data suggest caution on near-term upside.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $4.82entry
- T+1 · 8mo ago −1.24%α −1.72% · $4.76
- T+5 · 7mo ago +1.87%α −1.75% · $4.91
- T+20 · 7mo ago +13.28%α +3.40% · $5.46
- T+60 · 5mo ago +28.22%α +14.06% · $6.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Abeona Therapeutics announced the activation of NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center for ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). This expansion increases patient access in the Northeast and strengthens commercial distribution of the therapy, though no new financial or clinical data was provided.
Key Facts
- NewYork-Presbyterian/Columbia University Irving Medical Center is now the fifth Qualified Treatment Center (QTC) for ZEVASKYN.
- ZEVASKYN is the first and only autologous cell sheet-based gene therapy approved for RDEB, a rare and severe genetic skin disorder.
- No financial figures, patient enrollment updates, or clinical results were disclosed in the release.
- The announcement focuses on commercial infrastructure expansion, not product performance or regulatory milestones.
Financial Impact
Minimal near-term financial impact; expands commercial footprint without immediate revenue disclosure.
Risk Factors
- Commercial execution risk: Limited number of QTCs may constrain patient access and revenue generation.
- Manufacturing scalability: Abeona must produce sufficient ZEVASKYN batches to meet demand across expanding centers.
- Market size uncertainty: RDEB is ultra-rare, limiting total addressable market potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267338 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers